ACM
PTCT icon

ADAR1 Capital Management’s PTC Therapeutics PTCT Stock Holding History

ADAR1 Capital Management’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-50,023
Closed -$2.55M – 231
2025
Q1 		$2.55M Buy
50,023
+2,000
+4% +$99.8K 0.47% 52
2024
Q4 		$2.17M Buy
48,023
+28,023
+140% +$1.2M 0.43% 46
2024
Q3 		$742K Buy
+20,000
New +$670K 0.12% 93

Other funds holding PTCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ADAR1 Capital Management's PTCT Position: Q2 2025 in Review

ADAR1 Capital Management sold out of PTC Therapeutics (PTCT) in Q2 2025, closing a stake of 50,023 shares — an estimated $2.55M sold.

ADAR1 Capital Management first reported a position in PTCT in Q3 2024 and held it in 3 quarters. The position peaked at $2.55M in Q1 2025. 283 funds tracked by Wall St. Rank hold PTCT as of Q2 2025.

  • ADAR1 Capital Management reported no remaining PTC Therapeutics position as of Q2 2025 after selling out during the quarter.
  • ADAR1 Capital Management sold 50,023 PTC Therapeutics shares in Q2 2025, an estimated $2.55M.
  • ADAR1 Capital Management first reported a position in PTC Therapeutics in Q3 2024 and held it in 3 quarters.
  • ADAR1 Capital Management's PTC Therapeutics position peaked at $2.55M in Q1 2025.
  • 283 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2025.

Based on ADAR1 Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.